Novel inflammation-based model for postoperative early recurrence prediction of hepatitis B virus-related hepatocellular carcinoma ≤ 5 cm

Figure 2 Construction and evaluation of an inflammation-related score model based on various inflammation indices for predicting early recurrence of hepatitis B virus-related hepatocellular carcinoma ≤ 5 cm. A and B: Screening of inflammation indices for inflammation-related score (IRS) model construction using least absolute shrinkage and selection operator regression in the training cohort; C: Coefficients of each inflammation index integrated into the IRS model in the training cohort; D: Early recurrence-free survival (RFS) curves for hepatocellular carcinoma (HCC) patients with high and low IRS in the training cohort; E: Receiver operating characteristic (ROC) curves of IRS and inflammation indices on 1- and 2-year RFS of HCC patients in the training cohort; F: Early RFS curves for HCC patients with high and low IRS in the validation cohort; G: ROC curves of IRS and inflammation indices on 1- and 2-year RFS of HCC patients in the validation cohort. ALBI: Albumin-bilirubin index; ALRI: Aspartate aminotransferase to lymphocyte ratio index; ANRI: Aspartate aminotransferase to neutrophil ratio index; APRI: Aspartate aminotransferase to platelet ratio index; GPR: Gamma-glutamyl transpeptidase-to-platelet ratio; PNI: Prognostic nutritional index; RFS: Recurrence-free survival; IRS: Inflammation-related score; AUC: Areas under the curve.